Page 124 - Binder2
P. 124
That’s the idea behind tolerogenic adjuvants—compounds
that accompany the biologic and signal, “This is safe.”
Examples include:
• Rapamycin-loaded nanoparticles, which suppress
dendritic cell activation and promote Treg induction
• Mucosal adjuvants that stimulate IL-10 production
and dampen Th1/Th17 responses
• Hydrogel scaffolds that release antigen slowly in a
microenvironment biased toward regulation, not
activation
In autoimmune disease models, these tools have already
demonstrated their ability to reverse established
immunity and restore tolerance to specific antigens. While
most are in preclinical development, they represent a
powerful new paradigm: drugs that don’t just function
pharmacologically—but also coach the immune system
through a behavioral shift.
The Blueprint Is Already Being Written
Across all of these platforms, one truth is emerging:
immune cooperation is a design problem—and it's
solvable.
The ingredients are here:
• Delivery routes that induce tolerance
• Expression systems that reduce immune friction
• Adjuvants that promote regulatory responses
• Formulations that teach, not threaten
122
